Pharmacological AR inhibition (e.g., with enzalutamide) restores sensitivity to BRAF/MEKi in both sexes thus enhances treatment efficacy, and providing a compelling rationale for combination therapy approaches in melanoma. Here, BRAF is linked to melanoma.